MedTrace Logo

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

NCT00819767 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2011-06-28

Study results available
· View outcomes & findings →

Summary

This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.

Conditions

Interventions

DRUG

Aliskiren

Aliskiren was supplied in 150 mg tablets.

DRUG

Valsartan

Valsartan was supplied in 160 mg capsules.

DRUG

Placebo to aliskiren

Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.

DRUG

Placebo to valsartan

Placebo to valsartan was supplied in capsules matching valsartan 160 mg.

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Czechia
  • Hungary
  • Singapore
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819767 on ClinicalTrials.gov